Short Interest in Evogene Ltd. (NASDAQ:EVGN) Increases By 263.7%

Evogene Ltd. (NASDAQ:EVGN) saw a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 272,348 shares, a growth of 263.7% from the January 29th total of 74,880 shares. Based on an average daily volume of 2,291,022 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.5% of the company’s stock are short sold. Approximately 5.5% of the company’s stock are short sold. Based on an average daily volume of 2,291,022 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Evogene

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its holdings in Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 36,206 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Evogene during the fourth quarter valued at approximately $25,000. Institutional investors own 10.40% of the company’s stock.

Evogene Trading Up 4.6%

NASDAQ EVGN opened at $0.88 on Thursday. The company has a market cap of $4.71 million, a P/E ratio of -1.75 and a beta of 1.35. The company has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $1.15. Evogene has a 12-month low of $0.81 and a 12-month high of $2.42.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.